Leap Therapeutics And MacroGenics Among Early Winners And Losers At ESMO

Contrasting Market Reception For Rivals In GI Cancer

 
• By Andrew McConaghie

Two companies looking to challenge Merck’s Keytruda with new combinations have had contrasting reactions from investors

Concerns about safety and tough competition in the oncology market weighed on MacroGenics shares.

More from Business

More from Scrip